MedTrace Logo

Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers

NCT00638872 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2012-09-11

No results posted yet for this study

Summary

The main objective of the study is to evaluate the efficacy of the polydeoxyribonucleotide in improving the healing of diabetic foot ulcers.

Conditions

  • Diabetic Ulcer
  • Foot Ulcer Unhealed

Interventions

DRUG

Polydeoxyribonucleotide

3 times a week perilesional or intramuscular injections

OTHER

0.9% NaCl

same as PDRN

Sponsors & Collaborators

  • University of Messina

    lead OTHER

Principal Investigators

  • Giulia Cattarini · Mastelli srl, via Bussana Vecchia, Sanremo, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-12-31
Completion
2011-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638872 on ClinicalTrials.gov